Evidence map›Paper›PMID 41705193›Full record

ArticleJournal of onco-nephrology2026

Clinical practice pattern of management of plasma cell dyscrasia for kidney transplant candidates and recipients in the United States.

Samhita Boppana, Christopher D Blosser, Allison B Webber, Gaurav Gupta, Neeraj Singh, Samip Master, Raviprasenna Parasuraman, Erica L Campagnaro, Anuja Java, Ben Sprangers and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of onco-nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Samhita BoppanaDivision of Nephrology, Willis Knighton Medical Center, Shreveport, LA, USA.
Christopher D BlosserDivision of Nephrology, University of Washington and Fred Hutch, Seattle, WA, USA.
Allison B WebberDivision of Nephrology, University of California San Francisco, San Francisco, CA, USA.
Gaurav GuptaDivision of Nephrology, Virginia Commonwealth University, Richmond, VA, USA.
Neeraj SinghDivision of Nephrology, Willis Knighton Medical Center, Shreveport, LA, USA.
Samip MasterDivision of Hematology Oncology, Willis Knighton Medical Center, Shreveport, LA, USA.
Raviprasenna ParasuramanDivision of Nephrology, University of Michigan, Ann Arbor, MI, USA.
Erica L CampagnaroDivision of Hematology, University of Michigan, Ann Arbor, MI, USA.
Anuja JavaDivision of Nephrology Washington University in St. Louis, Saint Louis, MO, USA.
Ben SprangersBiomedical Research Institute, Department of Immunology and Infection, UHasselt, Diepenbeek, Belgium.
Bhavna Bhasin-ChhabraDivision of Nephrology, Mayo Clinic, Scottsdale, AZ, USA.
Erik L LumDivision of Nephrology, University of California Los Angeles, Los Angeles, CA, USA.
Diala KhirfanDivision of Nephrology, Tulane University, New Orleans, LA, USA.
Mariam AlexanderDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Nelson LeungDivision of Nephrology, Mayo Clinic, Rochester, MN, USA.
Heather LandauDivision of Hematology Oncology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
Naoka MurakamiDivision of Nephrology Washington University in St. Louis, Saint Louis, MO, USA.

Funding

Protection of kidney from autoimmunity by modulating co-stimlatory signalingK08DK120868 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI MURAKAMI, NAOKA · 2019 to 2023
$886k
NIDDK NIH HHS K08 DK120868
6 · The paper itself

Abstract

Background: Plasma cell dyscrasia (PCD) is a rare but important cause of end stage kidney disease (ESKD). Kidney transplant is the treatment of choice in patients with ESKD. However, the complexity of PCD care and risk of disease recurrence poses challenges to kidney transplant candidacy and outcomes. We examined the current clinical practice patterns of clinicians who care for patients with PCD and identified barriers to kidney transplantation for patients with PCD. Methods: A web-based survey was developed and distributed from January to July 2024 to kidney transplant clinicians (American Society of Transplant (AST) members), hematologists (PCD experts), and onco-nephrologists. Results: Seventy clinicians (50 transplant nephrologists, 18 hematologists, and two surgeons) from 42 transplant centers in the US participated in the survey. Clinical practice patterns pre and post kidney transplant for patients with PCD are highly variable among institutions, and only 36% reported having a protocol for pre- and post-transplant management for patients with PCD. Particularly, the requirement for pre-transplant hematologic remission criteria, induction and maintenance immunosuppression regimens and protocols for prophylaxis and screening for opportunistic infection are areas of future study. Clinicians listed lack of data and practice guidance as well as communication challenges among multiple specialties especially hematology and kidney transplant clinicians as notable barriers. Conclusions: Our study identified the highly variable current practice patterns when evaluating and managing patients with PCD for kidney transplant. Our findings emphasize the need for collecting and sharing clinical data to support standardized practices and serve as a basis for the upcoming multi-societal management recommendation for kidney transplant for patients with PCD.

Indexed as

AL amyloidosiskidney transplantmultiple myelomaplasma cell dyscrasiapractice pattern

Identifiers

PMID41705193
PMCPMC12908620

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.